Market Overview

Global Alpha-1 Antitrypsin Drugs Market 2018-2022 - One Driver Influencing this Market is the Improving Diagnosis of Alpha-1 Antitrypsin Deficiency

Share:

Global Alpha-1 Antitrypsin Drugs Market 2018-2022 - One Driver Influencing this Market is the Improving Diagnosis of Alpha-1 Antitrypsin Deficiency

PR Newswire

DUBLIN, Aug 28, 2018 /PRNewswire/ --

Research and Markets Logo. (PRNewsFoto/Research and Markets) (PRNewsfoto/Research and Markets)

The "Global Alpha-1 Antitrypsin Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. 

The Global Alpha-1 Antitrypsin Drugs Market to grow at a CAGR of 10.64% during the period 2018-2022.

The report, Alpha-1 Antitrypsin Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the revenue generated from the sales of alpha-1 antitrypsin drugs across the globe.

One trend affecting this market is strategic alliances and mergers. Companies are now working together in the form of collaboration or licensing for development of new drugs across location.

According to the report, one driver influencing this market is the improving diagnosis of alpha-1 antitrypsin deficiency. Detection is an important step in treating any disease or deficiency and several awareness programs have been conducted across the globe to recognize and differentiate alpha-1 antitrypsin deficiency from other diseases.

Further, the report states that one challenge affecting this market is the high cost of drugs. The high cost of alpha-1 antitrypsin therapies is responsible for impeding the market growth. The manufacture of plasma proteins is expensive and account almost four times the cost of manufacturing the pharmaceutical drugs.

Key vendors


  • Shire
  • CSL
  • GRIFOLS
  • Kamada

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis

PART 05: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition

PART 07: MARKET SEGMENTATION ROUTE OF ADMINISTRATION
- Segmentation by route of administration
- Comparison by Route of Administration
- Parenteral
- Inhalation
- Market opportunity by RoA

PART 08: CUSTOMER LANDSCAPE

PART 09: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas
- EMEA
- APAC
- Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario

PART 14: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- CSL
- GRIFOLS
- Kamada
- Shire

PART 15: PIPELINE ANALYSIS
- Pipeline analysis

PART 16: APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/m9pslt/global_alpha1?w=5


Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 



Cision View original content with multimedia:http://www.prnewswire.com/news-releases/global-alpha-1-antitrypsin-drugs-market-2018-2022---one-driver-influencing-this-market-is-the-improving-diagnosis-of-alpha-1-antitrypsin-deficiency-300703254.html

SOURCE Research and Markets

View Comments and Join the Discussion!